Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Research

Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study

Authors: Iyar Mazar, Jonathan Stokes, Sarah Ollis, Emily Love, Ashlee Espensen, Peter G. Barth, John H. Powers III, Alan L. Shields

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Barth syndrome (BTHS, OMIM 302060) is a rare, life-threatening, x-linked genetic disorder that occurs almost exclusively in males and is characterized by cardiomyopathy, neutropenia, skeletal muscle myopathy primarily affecting larger muscles, and shorter stature in youth. A greater number of individuals with BTHS are now surviving into adulthood due to advancements in diagnosis and disease management. Given these improvements in life expectancy, understanding the disease experience over time has become increasingly important to individuals with the condition, treatment developers, and regulatory agencies. A study was conducted to explore the experience of BTHS from the perspective of adult males at least 35 years of age with the condition via in-depth qualitative interviews.

Results

Findings showed that adults with BTHS experienced a variety of signs/symptoms with variable onset and severity throughout their lives, the most frequently reported being the symptoms of tiredness, muscle weakness, and a fast and/or irregular heart rate, and the sign of short stature in youth. These signs/symptoms negatively impacted individuals’ emotional, physical, social, and role functioning. Tiredness and weakness impacted some individuals’ physical functioning from an early age and into adulthood. These symptoms generally worsened over time, increasingly interfering with individuals’ ability to fully participate in paid and unpaid labor and to partake in family and leisure activities.

Conclusions

This research complements recent studies characterizing the potentially degenerative and progressive nature of BTHS and can encourage future research into the natural history and progression of BTHS in untreated individuals. Participants’ interview responses revealed a range of symptoms and the potential for multiple impacts on individuals’ physical, social, emotional, and role functioning as a result of BTHS symptoms, yet also revealed variability in severity of experience as well as the possibility of resilience and adaptation to the condition.
Appendix
Available only for authorised users
Literature
3.
go back to reference Spencer CT, Bryant RM, Day J, Gonzalez IL, Colan SD, Thompson WR, et al. Cardiac and clinical phenotype in Barth syndrome. Pediatrics. 2006;118(2):e337–46.CrossRef Spencer CT, Bryant RM, Day J, Gonzalez IL, Colan SD, Thompson WR, et al. Cardiac and clinical phenotype in Barth syndrome. Pediatrics. 2006;118(2):e337–46.CrossRef
4.
go back to reference Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5. Is responsible for Barth syndrome. Nat Genet. 1996;12(4):385–9.CrossRef Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5. Is responsible for Barth syndrome. Nat Genet. 1996;12(4):385–9.CrossRef
5.
go back to reference Jefferies JL. Barth syndrome. Am J Med Genet C: Semin Med Genet. 2013;163(3):198–205.CrossRef Jefferies JL. Barth syndrome. Am J Med Genet C: Semin Med Genet. 2013;163(3):198–205.CrossRef
6.
go back to reference Rigaud C, Lebre AS, Touraine R, Beaupain B, Ottolenghi C, Chabli A, et al. Natural history of Barth syndrome: a national cohort study of 22 patients. Orphanet journal of rare diseases. 2013;8:70.CrossRef Rigaud C, Lebre AS, Touraine R, Beaupain B, Ottolenghi C, Chabli A, et al. Natural history of Barth syndrome: a national cohort study of 22 patients. Orphanet journal of rare diseases. 2013;8:70.CrossRef
7.
go back to reference Roberts AE, Nixon C, Steward CG, Gauvreau K, Maisenbacher M, Fletcher M, et al. The Barth syndrome registry: distinguishing disease characteristics and growth data from a longitudinal study. Am J Med Genet A. 2012;158a(11):2726–32.CrossRef Roberts AE, Nixon C, Steward CG, Gauvreau K, Maisenbacher M, Fletcher M, et al. The Barth syndrome registry: distinguishing disease characteristics and growth data from a longitudinal study. Am J Med Genet A. 2012;158a(11):2726–32.CrossRef
8.
go back to reference Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, et al. Barth syndrome. Orphanet journal of rare diseases. 2013;8:23.CrossRef Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, et al. Barth syndrome. Orphanet journal of rare diseases. 2013;8:23.CrossRef
9.
go back to reference Ronvelia D, Greenwood J, Platt J, Hakim S, Zaragoza MV. Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle. Mol Genet Metab. 2012;107(3):428–32.CrossRef Ronvelia D, Greenwood J, Platt J, Hakim S, Zaragoza MV. Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle. Mol Genet Metab. 2012;107(3):428–32.CrossRef
10.
go back to reference Stokes J, Mazar I, Ollis S, Love E, Espensen A, Shields AL. Understanding the life experience of Barth syndrome from the perspective of older individuals. Barth Symptom Foundation international scientific, Medical & Family Conference; Clearwater, FL. July 2018:16–20. Stokes J, Mazar I, Ollis S, Love E, Espensen A, Shields AL. Understanding the life experience of Barth syndrome from the perspective of older individuals. Barth Symptom Foundation international scientific, Medical & Family Conference; Clearwater, FL. July 2018:16–20.
11.
go back to reference US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009.
12.
go back to reference Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59–65.CrossRef Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59–65.CrossRef
13.
go back to reference Folkman S, Lazarus RS, Dunkel-Schetter C, DeLongis A, Gruen RJ. Dynamics of a stressful encounter: cognitive appraisal, coping, and encounter outcomes. J Pers Soc Psychol. 1986;50(5):992–1003.CrossRef Folkman S, Lazarus RS, Dunkel-Schetter C, DeLongis A, Gruen RJ. Dynamics of a stressful encounter: cognitive appraisal, coping, and encounter outcomes. J Pers Soc Psychol. 1986;50(5):992–1003.CrossRef
14.
go back to reference Bowron A, Honeychurch J, Williams M, Tsai-Goodman B, Clayton N, Jones L, et al. Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype. J Inherit Metab Dis. 2015;38(2):279–86.CrossRef Bowron A, Honeychurch J, Williams M, Tsai-Goodman B, Clayton N, Jones L, et al. Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype. J Inherit Metab Dis. 2015;38(2):279–86.CrossRef
15.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRef Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRef
16.
go back to reference Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839–42.CrossRef Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839–42.CrossRef
17.
go back to reference Thompson WR, DeCroes B, McClellan R, Rubens J, Vaz FM, Kristaponis K, et al. New targets for monitoring and therapy in Barth syndrome. Genetics in medicine : official journal of the American College of Medical Genetics. 2016;18(10):1001–10.CrossRef Thompson WR, DeCroes B, McClellan R, Rubens J, Vaz FM, Kristaponis K, et al. New targets for monitoring and therapy in Barth syndrome. Genetics in medicine : official journal of the American College of Medical Genetics. 2016;18(10):1001–10.CrossRef
Metadata
Title
Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study
Authors
Iyar Mazar
Jonathan Stokes
Sarah Ollis
Emily Love
Ashlee Espensen
Peter G. Barth
John H. Powers III
Alan L. Shields
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1200-8

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue